Quadcap Wealth Management LLC Invests $459,000 in Gilead Sciences, Inc. $GILD

Key Points

• Quadcap Wealth Management LLC acquired 4,093 shares of Gilead Sciences, Inc. for approximately $459,000 in the first quarter.
• Gilead's CEO sold 10,000 shares for about $1.14 million, reducing his stake by 1.62%, while the company's stock recently reported $2.01 EPS for the last quarter.
• The company announced a quarterly dividend of $0.79 per share, with a 2.8% yield, payable on September 29th to shareholders of record on September 15th.

Quadcap Wealth Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,093 shares of the biopharmaceutical company's stock, valued at approximately $459,000.

Other institutional investors also recently modified their holdings of the company. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences in the 1st quarter valued at $25,000. Goodman Advisory Group LLC bought a new position in Gilead Sciences in the 1st quarter valued at $29,000. Colonial Trust Advisors raised its position in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Core Alternative Capital raised its position in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. Finally, IMA Advisory Services Inc. bought a new position in Gilead Sciences in the 1st quarter valued at $39,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company's stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the transaction, the chief executive officer directly owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,371,330 in the last three months. Insiders own 0.27% of the company's stock.

Gilead Sciences Trading Up 0.4%

NASDAQ GILD traded up $0.41 on Friday, reaching $112.97. The company had a trading volume of 4,629,720 shares, compared to its average volume of 6,327,395. The stock's 50 day moving average is $113.01 and its 200-day moving average is $109.63. The stock has a market cap of $140.17 billion, a price-to-earnings ratio of 22.50, a PEG ratio of 0.70 and a beta of 0.33. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52 week low of $77.74 and a 52 week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's payout ratio is presently 62.95%.

Analysts Set New Price Targets

Several brokerages have issued reports on GILD. UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price for the company in a research report on Tuesday, August 19th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a research report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.